$IGC

Investor interest is growing in four small-cap stocks: VivoSim Labs (VIVS), IGC Pharma (IGC), Algorhythm Holdings (RIME), and Xiao-I (AIXI). VIVS reported a $5M milestone payment from Eli Lilly and targets 500%+ revenue growth. IGC beat Q2 estimates and expects Alzheimer's trial results in Q4. RIME is exploring strategic alternatives for its SemiCab AI logistics business. AIXI focuses on enterprise AI solutions. All four stocks trade near $0.30.

The article highlights microcaps with near-term catalysts. Kartoon Studios (TOON) reported Q2 2026 revenue of about $5.8M and EPS about $0.38, including a $39.2M litigation settlement gain, and said an Amazon Prime Video deal will launch in Feb 2027. SurgePays (SURG) posted Q2 revenue up 40.7% to $16.2M and GAAP net income $1.29M. MDxHealth (MDXH) Q2 revenue rose 16% to $27.2M. IGC Pharma (IGC) expects Phase 2 topline results for IGC-AD1 in Q4 2026.

TheStreetReports highlights sub-$1 and microcap catalysts across several sectors. Planet Green Holdings (PLAG) says its lactoferrin sourcing and distribution entered commercial operations. Peraso (PRSO) added a PRM2145 60GHz mmWave module ahead of Q2 results. IGC (IGC) nears Phase 2 topline in Q4 2026; Fort (FRTT) agreed to buy 50.1% of Logia USA; Kartoon (TOON) has earnings Aug. 13; Algorhythm (RIME) reports Aug. 14.

IGC Pharma (NYSE American:IGC) said its Phase 2 CALMA trial of IGC-AD1 for agitation in Alzheimer’s dementia has randomized 160 participants and expects to close enrollment after up to eight additional randomizations. The company is adding regulatory, biostatistical, and AI-enabled data science support, including OPIS Research for EMA interactions, ahead of expected Q4 2026 topline results.

IGC Pharma (NYSE American: IGC) said it is evaluating potential civil remedies after a federal jury verdict in United States v. Andrew Left found Left guilty of securities fraud. The indictment named IGC in an alleged 2018 short campaign. IGC will assess possible recoverable damages, including market value, reputational and operational harm, and legal costs. The SEC said Anson Advisors paid $2.25M in penalties tied to trading profits.

IGC Pharma, Inc. (IGC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001326205 0001326205 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

IGC Pharma (NYSE American:IGC) said its beta Agentic Harmonization Assistant (AHA) is designed to speed harmonization of fragmented Alzheimer’s datasets. In internal testing on a 100-variable workflow, it cut time from 28 hours to 2.5 hours (90% reduction). The company plans to demonstrate AHA at AAIC 2026 in London and is advancing Phase 2 CALMA for IGC-AD1.

IGC Pharma, Inc. (IGC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. false 0001326205 0001326205 2026-06-05 2026-06-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Repor

New to The Street said its Bloomberg Television sponsored program airs May 30 at 6:30 PM ET, featuring interviews with executives across AI, healthcare, fintech, digital assets and commodities. Among guests: YesSmile.ai (AI for dental admin in a $200B market), Lantern Pharma (Zeta for rare cancers), Roadzen (AI for auto insurance), and Gold Royalty Corp. (250+ royalties/streams).

IGC Pharma, Inc. CEO Mukunda Ram acquired a total of 706,409 shares of common stock on April 1, 2026, through the exercise of restricted stock units and stock options. These transactions are described as routine compensation-related vesting and option exercises, not discretionary buying or selling. Following these acquisitions, Ram directly holds 4,649,088 shares, with an additional 910,751 shares held indirectly by his spouse.